H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says the company is the “pioneer of gene editing” and well positioned ahead of 2025 catalysts. The shares are undervalued ahead of “multiple defining inflection points” for 2025, including meaningful uptake in the Casgevy launch in sickle cell disease and and transfusion-dependent thalassemia, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
- Crispr Therapeutics price target lowered to $30 from $45 at Morgan Stanley
- Bargain Basement CRISPR Therapeutics Becomes Takeover Target
- RFK disclosures show holdings in Crispr, Dragonfly Therapeutics, STAT reports
- Crispr Therapeutics call volume above normal and directionally bullish